| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
83.76(B) |
| Last
Volume: |
7,531,744 |
Avg
Vol: |
8,742,055 |
| 52
Week Range: |
$64.58 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,230 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$890,904 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
3 |
5 |
9 |
14 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wilfong Diane E |
SVP, Controller & CAO |
• • – |
2020-11-10 |
4 |
D |
$60.62 |
$37,039 |
D/D |
(611) |
14,201 |
|
- |
|
| Wilfong Diane E |
SVP, Controller & CAO |
• • – |
2020-11-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,430 |
14,812 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2020-11-10 |
4 |
D |
$60.62 |
$146,458 |
D/D |
(2,416) |
2,685 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2020-11-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,101 |
5,101 |
|
- |
|
| Dickinson Andrew D |
EVP, Chief Financial Officer |
• • – |
2020-11-10 |
4 |
D |
$60.62 |
$84,807 |
D/D |
(1,399) |
16,286 |
|
- |
|
| Dickinson Andrew D |
EVP, Chief Financial Officer |
• • – |
2020-11-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,046 |
17,685 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2020-11-03 |
4 |
D |
$58.83 |
$722,550 |
D/D |
(12,282) |
17,906 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2020-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
26,270 |
30,188 |
|
- |
|
| Whitley Richard James |
Director |
• • – |
2020-10-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,434 |
31,122 |
|
- |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2020-08-17 |
4 |
AS |
$68.32 |
$12,434 |
D/D |
(182) |
0 |
|
-18% |
|
| Parsey Merdad |
Chief Medical Officer |
• • – |
2020-08-15 |
4 |
A |
$57.43 |
$10,452 |
D/D |
182 |
182 |
|
- |
|
| Dickinson Andrew D |
EVP, Chief Financial Officer |
• • – |
2020-08-10 |
4 |
D |
$68.51 |
$70,017 |
D/D |
(1,022) |
14,639 |
|
- |
|
| Dickinson Andrew D |
EVP, Chief Financial Officer |
• • – |
2020-08-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,306 |
15,661 |
|
- |
|
| Wilfong Diane E |
SVP, Controller & CAO |
• • – |
2020-08-10 |
4 |
D |
$68.51 |
$94,818 |
D/D |
(1,384) |
13,382 |
|
- |
|
| Wilfong Diane E |
SVP, Controller & CAO |
• • – |
2020-08-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,345 |
14,766 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2020-07-24 |
4 |
D |
$73.64 |
$264,147 |
D/D |
(3,587) |
3,918 |
|
- |
|
| Mercier Johanna |
Chief Commercial Officer |
• • – |
2020-07-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,505 |
7,505 |
|
- |
|
| Rodriguez Javier |
Director |
• • – |
2020-06-23 |
4 |
S |
$75.50 |
$14,270 |
D/D |
(189) |
0 |
|
22% |
|
| Rodriguez Javier |
Director |
– • – |
2020-06-15 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
189 |
|
- |
|
| Dickinson Andrew D |
EVP, Chief Financial Officer |
• • – |
2020-06-10 |
4 |
D |
$77.07 |
$130,325 |
D/D |
(1,691) |
13,355 |
|
- |
|
| Dickinson Andrew D |
EVP, Chief Financial Officer |
• • – |
2020-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,646 |
15,046 |
|
- |
|
| Whitley Richard James |
Director |
• • – |
2020-05-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,270 |
29,688 |
|
- |
|
| Manwani Harish |
Director |
• • – |
2020-05-05 |
4 |
D |
$79.14 |
$33,160 |
D/D |
(419) |
3,718 |
|
- |
|
| Manwani Harish |
Director |
• • – |
2020-05-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,270 |
4,137 |
|
- |
|
| Wold Olsen Per |
Director |
• • – |
2020-05-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,270 |
100,124 |
|
- |
|
2499 Records found
|
|
Page 12 of 100 |
|
|
0.64 (0.95%) 
